Ultragenyx said it is laying off about 20% of employees and scrapping a Wilson disease gene therapy program, marking a further portfolio and cost reset after a difficult clinical and operational period. The cuts are described as the second layoff by the company this year. The news follows a period in which Ultragenyx reported both regulatory progress and setbacks, including FDA approvals and a major failure in Angelman syndrome earlier in the year. The company’s action signals a renewed focus on reducing burn and reallocating resources toward assets with clearer development paths. The decision to stop the Wilson disease gene therapy program suggests the company has determined that risk/reward no longer justifies continued investment in that pipeline branch. For biotech investors and employees, this is a concrete example of how efficacy or trial outcomes can drive rapid structural changes even after recent regulatory wins.